We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Stretta System Effective for GERD in Obese Patients

By HospiMedica staff writers
Posted on 21 Jul 2004
A clinical study has found that the Stretta system is highly effective in treating gastroesophageal reflux disease (GERD) in obese patients as well as those who had previously undergone unsuccessful antireflux surgery.

The Stretta system consists of the Stretta catheter, which is a disposable, flexible catheter, and the control module. More...
Using the system, a doctor delivers temperature-controlled radiofrequency energy to create thermal lesions in the muscle of the lower esophageal function, which improves GERD symptoms, reduces acid exposure, and reduces the need for antisecretory medication. The Stretta system was developed by Curon Medical, Inc. (Fremont, CA, USA).

"We intentionally included a group of difficult-to-treat GERD patients,” said principal investigator Dr. W. Scott Melvin, chief of the division of general surgery at Ohio State University Medical Center (Columbus, USA). "Among these were ten patients who had previously undergone antireflux surgery, but still had persistent or recurrent GERD symptoms, as well as 18 patients who were obese and therefore considered poor surgical candidates.”

All patients showed significant symptom improvement, even in the subgroup of obese patients and in the group who had failed previous antireflux surgery. A Scandinavian study in 2003 showed that people who were overweight or obese may be up to six times more likely to have GERD than people with normal body weight.



Related Links:
Curon Medical
Ohio State University

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
LED Surgical Lamp
ACEMST35/57
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.